Davinder Brar a former managing director at Ranbaxy Laboratories, spoke to Business Standard on phone from New Delhi on his views on Ranbaxy founders' decision to sell their stake.

<tr><td><p class='TableClas'></p><P class='TableClas'> <DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>
</p><p class='TableClas'>Ranbaxy's founders Malvinder Singh and his family sold their entire stake -- 34.82 per cent stake -- in the company to Japan's Daiichi Sankyo for as much as $4.6 billion. 
</p><p class='TableClas'>
</p><p class='TableClas'><STRONG>Your views on the Ranbaxy-Daiichi deal

Web excl: D S Brar on the Ranbaxy-Daiichi deal

Also Read

BGR Energy Q4 net at Rs 32 cr

Deccan Cements Q4 net up 37%

iGATE opens Australian ICT facility in Ballarat

Videocon to start telecom services from Chennai

Property prices in Mumbai to fall by upto 15%

Explore News